Cargando…

High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment

Mirabegron, which was the first β3-adrenoceptor agonist introduced for use in clinical practice, has been extensively evaluated in overactive bladder (OAB) patients in several phase II and III studies. However, most of the enrolled patients were treatment naive or had experienced a wash-out period b...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Chun-Hou, Kuo, Hann-Chorng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106046/
https://www.ncbi.nlm.nih.gov/pubmed/27828840
http://dx.doi.org/10.1097/MD.0000000000004962